Printer Friendly

ONCOLOGIX TO LICENSE BOEHRINGER INGELHEIM LUNG CANCER DRUG

 GAITHERSBURG, Md., Oct. 6 /PRNewswire/ -- Oncologix, Inc., today announced the signing of an Agreement in Principle with Boehringer Ingelheim of Germany for the worldwide exclusive rights to a drug, designated as OLX-102, to be used in the treatment of non-small cell lung cancer as adjuvant therapy. Under the terms of the agreement, Boehringer Ingelheim has reserved exclusive rights to manufacture and market OLX-102 in Europe.
 "We're very excited about this drug's potential to increase survival of patients with this type of lung cancer, and as it relates to the success of our in-licensing strategy," Oncologix President and Chief Executive Officer Charles N. Blitzer stated. "We anticipate a definitive agreement being concluded some time before the end of the year."
 According to American Cancer Society estimates, in the United States there will be 170,000 new cases of lung cancer in 1993, of which 75 percent are diagnosed as non-small cell. Treatment is determined by the extent of disease and can include chemotherapy alone or combined with radiation and/or surgery. OLX-102 will be given as an adjuvant to these therapies.
 Oncologix is a development-stage company that provides novel differentiated therapies for the treatment of cancer, its symptoms and the side effects associated with current cancer therapies. Oncologix is located in Gaithersburg.
 -0- 10/6/93
 /CONTACT: Charles N. Blitzer, president and chief executive officer, of Oncologix, 301-258-3401/


CO: Oncologix, Inc.; Boehringer Ingelheim ST: Maryland IN: MTC SU:

KD-MH -- DC008 -- 9281 10/06/93 10:58 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 6, 1993
Words:246
Previous Article:SPRINT, MSCI ENTER JOINT MARKETING AGREEMENT TO COMBINE ATM AND SUPERCOMPUTERS
Next Article:ITC FINDS LIKELY INJURY FROM ITALIAN AND JAPANESE GRAIN-ORIENTED ELECTRICAL STEEL
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters